Marco Allinovi

Dr. Marco Allinovi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
TMTommaso Mazzierli
Tommaso Mazzierli
FAFederica Allegretta
Federica Allegretta
EMEnrico Maffini
Enrico Maffini
MAMarco Allinovi
Marco Allinovi
Drug-induced thrombotic microangiopathy (DITMA) represents 10%–13% of all thrombotic microangiopathy (TMA) cases and about 20%–30% of secondary TMAs, just behind pregnancy-related and infection-related forms. Although the list of drugs potentially involved as causative for TMA are rapidly increasing, the scientific literature on DITMA is quite scarce (mostly as individual case reports or little case series), leading to poor knowledge of pathophysiological mechanisms and clinical management. In this review, we focused on these critical aspects regarding DITMA. We provided an updated list of TMA-associated drugs that we selected from a scientific literature review, including only those drugs with a definite or probable causal association with TMA. The list of drugs is heterogeneous and could help physicians from several different areas to be familiar with DITMA. We describe the clinical features of DITMA, presenting the full spectrum of clinical manifestations, from systemic to kidney-limited forms. We also analyze the association between signs/symptoms (i.e., malignant hypertension, thrombocytopenia) and specific DITMA causative drugs (i.e., interferon, ticlopidine). We highlighted their multiple different pathophysiological mechanisms, being frequently classified as immune-mediated (idiosyncratic) and dose-related/toxic. In particular, to clarify the role of the complement system and genetic deregulation of the related genes, we conducted a revision of the scientific literature searching for DITMA cases who underwent renal biopsy and/or genetic analysis for complement genes. We identified a complement deposition in renal biopsies in half of the patients (37/66; 57%), with some drugs associated with major deposits (i.e., gemcitabine and ramucirumab), particularly in capillary vessels (24/27; 88%), and other with absent deposits (tyrosine kinase inhibitors and intraocular anti-VEGF). We also found out that, differently from other secondary TMAs (such as pregnancy-related-TMA and malignant hypertension TMA), complement genetic pathological mutations are rarely involved in DITMA (2/122, 1.6%). These data suggest a variable non-genetic complement hyperactivation in DITMA, which probably depends on the causative drug involved. Finally, based on recent literature data, we proposed a treatment approach for DITMA, highlighting the importance of drug withdrawal and the role of therapeutic plasma-exchange (TPE), rituximab, and anti-complementary therapy.

5 May 2017 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
MCMarta Calatroni
Marta Calatroni
EOElena Oliva
Elena Oliva
DGDavide Gianfreda
Davide Gianfreda
GGGina Gregorini
Gina Gregorini
MAMarco Allinovi
Marco Allinovi
AVAugusto Vaglio
Augusto Vaglio
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare systemic diseases that usually occur in adulthood. They comprise granulomatosis with polyangiitis (GPA, Wegener’s), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome). Their clinical presentation is often heterogeneous, with frequent involvement of the respiratory tract, the kidney, the skin and the joints. ANCA-associated vasculitis is rare in childhood but North-American and European cohort studies performed during the last decade have clarified their phenotype, patterns of renal involvement and their prognostic implications, and outcome. Herein, we review the main clinical and therapeutic aspects of childhood-onset ANCA-associated vasculitis, and provide preliminary data on demographic characteristics and organ manifestations of an Italian multicentre cohort.

3 October 2024 in Kidney International
Verified
Journal Article
Open access
VRValentina Raglianti
Valentina Raglianti
MAMaria Lucia Angelotti
Maria Lucia Angelotti
LCLuigi Cirillo
Luigi Cirillo
FRFiammetta Ravaglia
Fiammetta Ravaglia
SLSAMUELA LANDINI
SAMUELA LANDINI
PRPaola Romagnani
Paola Romagnani
Podocytopathies represent a group of glomerular disorders associated with minimal changes (MC) or focal segmental glomerulosclerosis (FSGS) lesion patterns at biopsy and heterogeneous responses to steroids. Anti-nephrin antibodies were previously found in such patients, suggesting an autoimmune form of podocytopathy. High resolution confocal microscopy on kidney biopsies of a cohort of 128 pediatric patients revealed localization of IgG along the slit diaphragm in 30% of patients with MC and 25% of those with FSGS, but not in other lesion patterns. Anti-nephrin IgG ELISA assay in the serum and stimulated emission depletion microscopy of kidney biopsies showed IgG-nephrin co-localization only in 77.8% of cases. Similar observations were obtained in a cohort of 48 adult patients with MC or FSGS at kidney biopsy, where IgG-nephrin colocalization was only 44.4%, suggesting the existence of autoantibodies binding to other slit proteins. Patients with anti-slit antibodies showed nephrotic syndrome at onset in 94.4% of cases. Patients with primary steroid-resistance had anti-slit antibodies in 27%, while those with secondary steroid-resistance in 87.5% of cases, irrespective of the histopathological lesion pattern. Steroid-resistant patients with anti-slit antibodies responded to second-line immunosuppressants in 92.3% vs. only 20% of patients that were anti-slit negative. No patient with anti-slit antibodies developed kidney failure vs. 51.7% of those negative for antibodies (66.7% with a genetic cause and 41.2% with a non-genetic cause). Thus, the detection of anti-slit antibodies can identify patients with an autoimmune podocytopathy responsive to treatment with second-line immunosuppressants, irrespective of the histopathological lesion pattern at biopsy.

29 June 2017 in IEEE Transactions on Medical Imaging
Verified
Journal Article
Open access
Nantheera AnantrasirichaiNantheera Anantrasirichai
Nantheera Anantrasirichai
WHWesley Hayes
Wesley Hayes
MAMarco Allinovi
Marco Allinovi
DBDavid Bull
David Bull
Alin AchimAlin Achim
Alin Achim
This paper presents a novel method for line restoration in speckle images. We address this as a sparse estimation problem using both convex and non-convex optimization techniques based on the Radon transform and sparsity regularization. This breaks into subproblems, which are solved using the alternating direction method of multipliers, thereby achieving line detection and deconvolution simultaneously. We include an additional deblurring step in the Radon domain via a total variation blind deconvolution to enhance line visualization and to improve line recognition. We evaluate our approach on a real clinical application: the identification of B-lines in lung ultrasound images. Thus, an automatic B-line identification method is proposed, using a simple local maxima technique in the Radon transform domain, associated with known clinical definitions of line artefacts. Using all initially detected lines as a starting point, our approach then differentiates between B-lines and other lines of no clinical significance, including Z-lines and A-lines. We evaluated our techniques using as ground truth lines identified visually by clinical experts. The proposed approach achieves the best B-line detection performance as measured by the F score when a nonconvex Ip regularization is employed for both line detection and deconvolution. The F scores as well as the receiver operating characteristic (ROC) curves show that the proposed approach outperforms the state-of-the-art methods with improvements in B-line detection performance of 54%, 40%, and 33% for F 0.5 , F 1 , and F 2 , respectively, and of 24% based on ROC curve evaluations.

25 March 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Anna Julie PeiredAnna Julie Peired
Anna Julie Peired
GAGiulia Antonelli
Giulia Antonelli
MAMaria Lucia Angelotti
Maria Lucia Angelotti
MAMarco Allinovi
Marco Allinovi
FGFrancesco Guzzi
Francesco Guzzi
PRPaola Romagnani
Paola Romagnani
Papillary renal cell carcinoma derives from renal progenitors in an adenoma-carcinoma sequence, and acute kidney injury is a preventable risk factor.

30 January 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
VRValentina Raglianti
Valentina Raglianti
MAMaria Lucia Angelotti
Maria Lucia Angelotti
LCLetizia De Chiara
Letizia De Chiara
MAMarco Allinovi
Marco Allinovi
LCLuigi Cirillo
Luigi Cirillo
PRPaola Romagnani
Paola Romagnani
An abstract is unavailable. This article is available as a PDF only.